RICHMOND, Calif., March 19, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. SGMO -1.43% announced today that it has commenced a $100 million underwritten public offering of shares of its common stock. All of the shares in the offering are to be sold by Sangamo. Sangamo intends to grant the underwriters a 30 day option to purchase up to 15% of the number of shares of common stock sold in the offering. Sangamo intends to use the proceeds from this offering for working capital and other general corporate purposes, including support for continuing research and development of ZFP Therapeutic product candidates and research programs (including research stage programs for monogenic diseases and cancer immunotherapy), manufacturing capabilities for clinical and commercial production, clinical trials and business development activities and, if opportunities arise, acquisitions of businesses, products, technologies or licenses that are complementary to our business.
J.P. Morgan Securities LLC is acting as sole book-running manager for the offering.
A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission(the "SEC") and is effective. A preliminary prospectus supplement relating to the offering has been filed with the SEC. Copies of the preliminary prospectus supplement and accompanying prospectus may be obtained, when available, from the offices of J.P. Morgan Securities LLC, Attn: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
About Sangamo Sangamo BioSciences, Inc. is focused on Engineering Genetic Cures™ for monogenic and infectious diseases by deploying its novel DNA-binding protein technology platform in therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS (SB-728-T) and AAV-NGF for Alzheimer's disease (CERE-110). Sangamo's other therapeutic programs are focused on monogenic and rare diseases. The Company has formed a strategic collaboration with Shire International GmbH to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases, and with Biogen Idec Inc. for hemoglobinopathies, such as sickle cell disease and beta-thalassemia. It has also established strategic partnerships with companies in non-therapeutic applications of its technology, including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the Company's website at www.sangamo.com .
ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.
This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, the proposed public offering of shares of common stock. Actual results may differ materially from these forward-looking statements due to a number of factors, including risks and uncertainties related to whether or not Sangamo will be able to raise capital through the sale of shares of common stock, the final terms of the proposed offering, market and other conditions for the offering, and the satisfaction of customary closing conditions related to the proposed public offering. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. Additional risks and uncertainties relating to Sangamo and its business can be found under the heading "Risk Factors" in Sangamo's Annual Report on Form 10-K and other filings with the SEC, and in the preliminary prospectus supplement related to the proposed offering to be filed with the SEC on or about the date hereof. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.
SOURCE Sangamo BioSciences, Inc.
Copyright (C) 2014 PR Newswire. All rights reserved